scispace - formally typeset
C

Craig J. Peine

Researcher at Hennepin County Medical Center

Publications -  17
Citations -  3595

Craig J. Peine is an academic researcher from Hennepin County Medical Center. The author has contributed to research in topics: Hepatitis & Hepatitis C. The author has an hindex of 10, co-authored 16 publications receiving 3317 citations. Previous affiliations of Craig J. Peine include University of Minnesota.

Papers
More filters
Journal ArticleDOI

A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.

TL;DR: This Mayo TIPS model may predict early death following elective TIPS for either prevention of variceal rebleeding or for treatment of refractory ascites, superior to both the Child‐Pugh classification and the Child-Pugh score in predicting survival.
Journal ArticleDOI

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial

Ira M. Jacobson, +229 more
- 01 Oct 2007 - 
TL;DR: PEG‐IFN alfa‐2b plus weight‐based RBV is more effective than flat‐dose RBV, particularly in genotype 1 patients, providing equivalent efficacy across all weight groups, and RBV 1400 mg/day is appropriate for patients 105 to 125 kg.
Journal ArticleDOI

A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis

TL;DR: In this article, a pilot study demonstrated that the TNF-α-neutralizing molecule etanercept could be an effective treatment for patients with alcoholic hepatitis, which is a cause of major morbidity and mortality that lacks effective therapies.
Journal ArticleDOI

Objective Evaluation of Endoscopy Skills during Training

TL;DR: The goal of this study was to relate the acquisition of a few basic skills to the number of procedures using a simple, quick, and objective grading system for each procedure.
Journal ArticleDOI

A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis.

TL;DR: This is the first study to examine TNF inhibition with etanercept in patients with alcoholic hepatitis and the results support the rationale for larger controlled studies to further assess safety and efficacy.